Chemotherapy-Induced Pulmonary Hypertension: Role of Alkylating Agents
Ranchoux, Benoît × Günther, Sven Quarck, Rozenn Chaumais, Marie-Camille Dorfmüller, Peter Antigny, Fabrice Dumas, Sébastien J Raymond, Nicolas Lau, Edmund Savale, Laurent Jaïs, Xavier Sitbon, Olivier Simonneau, Gérald Stenmark, Kurt Cohen-Kaminsky, Sylvia Humbert, Marc Montani, David Perros, Frédéric #
American Journal of Pathology vol:185 issue:2 pages:356-71
Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonary hypertension (PH) characterized by progressive obstruction of small pulmonary veins and a dismal prognosis. Limited case series have reported a possible association between different chemotherapeutic agents and PVOD. We evaluated the relationship between chemotherapeutic agents and PVOD. Cases of chemotherapy-induced PVOD from the French PH network and literature were reviewed. Consequences of chemotherapy exposure on the pulmonary vasculature and hemodynamics were investigated in three different animal models (mouse, rat, and rabbit). Thirty-seven cases of chemotherapy-associated PVOD were identified in the French PH network and systematic literature analysis. Exposure to alkylating agents was observed in 83.8% of cases, mostly represented by cyclophosphamide (43.2%). In three different animal models, cyclophosphamide was able to induce PH on the basis of hemodynamic, morphological, and biological parameters. In these models, histopathological assessment confirmed significant pulmonary venous involvement highly suggestive of PVOD. Together, clinical data and animal models demonstrated a plausible cause-effect relationship between alkylating agents and PVOD. Clinicians should be aware of this uncommon, but severe, pulmonary vascular complication of alkylating agents.